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variables. Cox proportional harzards model was used to identify
risk factors for survival. Analyzed risk factors were: age, sex, diag-
nosis, disease stage, acute GVHD (grade II-IV), extensive
c-GVHD, stem cell source (cord blood x bone marrow), use of
antibodies directed to T-cells and HLA matching. Diagnosis were:
CML-46; AML/MDS-40, ALL-34, OTHERS-5. Male: 78; fe-
male: 44; median age 17 years (range: 1-55). Cell source was bone
marrow in 95 patients, cord blood in 30 patients. Conditioning
regimen was nomyeloablative in 8 patients and conventional in 114
patients. 25 patients received ATG or ALG as part of their con-
ditioning regimen and 90 patients received cyclophosphamide and
TBI. Sixty-six patients (53%) had advanced disease at the time of
transplant (CML advanced phase, AML or ALL in  second
remission, relapsed or refractory).
RESULTS: Acute GVHD grade II-IV was observed in 51 pa-
tients (41%) and was the primary cause of death in 9% of the
patients. Extensive chronic GVHD was observed in 32 patients
(26%) and was the primary cause of death in 13% of the patients.
Other causes of death included: infection in 32 (41%) and relapse
in 21 (27%) of the patients. Estimated 10 years overall survival was
40% with a median survival of 189 days. There was no difference
in survival according sex, diagnosis, stem cell source, type of con-
ditioning, number of cells infused or HLA compatibility. There
was a signiﬁcant better 10 years survival for early disease, compared
to advanced disease (55% x 20%; p0.0005), age less than 18 x
more than 18 (60% x 20%; p0.0012). Extensive c-GVHD was
protective for overall survival (P0.0340; Odds ratio 0.3998;
95% CI0.1758 to 0.9092).
CONCLUSIONS: 1) Estimated 10 y overall survival was 55%
for patients with early disease; 2) Extensive c-GVHD had a pro-
tective effect on OS, probably due to graft versus malignant effect.
3) Age less than 18 years and early disease were favorable risk
factors for survival.
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PLATEAU IN THE DISEASE-FREE SURVIVAL CURVE AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA MAY SIGNIFY CURE: A LONG-TERM SINGLE INSTITUTION
EXPERIENCE
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Bodensteiner, D.C.1, Lewis, J.L.1, Hoffmann, T.1, Curran, K.1,
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Introduction: Allogeneic Stem Cell Transplantation (AlloSCT)
through the graft-versus-leukemia (GVL) effect holds the promise
of a long-term cure in patients with acute myeloid leukemia
(AML).
Methods: In an attempt to examine whether AlloSCT provides
long-term disease control in patients with AML, we retrospectively
evaluated our experience and analyzed the outcomes of ASCT in
patients with AML from 1978 to 2005.
Results: Fifty-nine males and 46 females (n105) of median age
32 years (range: 5-60 years) were treated. Of these, 65 were in CR
at the time of transplantation, 40 patients were transplanted with
active disease. Fifty patients were transplanted in ﬁrst remission.
Bone marrow was used in 75 patients as the source of stem cells
prior to 1995 and peripheral blood stem cells (PBSC) were used in
30 patients. Ninety-four of 105 patients engrafted (90%). Median
time for neutrophil recovery was 16 days (range: 9-90 days) and 23
days (range: 9-106 days) for platelets. Median duration of fol-
low-up for those who did not succumb to early transplant-related
mortality (100 days) was 2 years (range: 102 days-21 years).
Median survival time of this cohort was 2 years. Of the 105
patients, 77 have died. Thirty-four patients (32%) died within
100-days of transplantation. Overall survival (OS) of all patients
who did not succumb to TRM was 47% at 5-years, 38% at
10-years and 15-years respectively. No relapse occurred after 4.25
years. OS in patients transplanted in CR (n65) at 5-years was
72%, and at 10 and 15-years was 62% respectively. For those
transplanted with disease (n40), a complete response was
achieved in 23 patients (22%), with a median survival of 214 days.
Disease status at transplantation was a signiﬁcant variable for
survival (p0.01). Most frequent cause of death was infection (27
out of 105 patients). Five patients developed late onset myelodys-
plastic syndrome/secondary malignancy. Patients with any graft-
versus-host-disease (GVHD) had better survival compared to pa-
tients with no GVHD, underscoring the role of GVL effect in
long-term disease control.
Conclusion: In conclusion, AlloSCT provides a possible cure in
a proportion of patients with AML as evidenced by a plateau in the
DFS curve after 4.25 years.
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REDUCED-INTENSITY STEM CELL TRANSPLANTATION IN PATIENTS
WITH HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
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Gonzalez-LLano, O.1, Gomez-Almaguer, D.1 1Servicio de Hematologia del
Hospital Universitario de la U.A.N.L., Monterrey, Nuevo Leon, Mexico;
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Introduction: Despite the optimal use of the antileukemic
agents, reported cure rates no exceed 40% in high-risk ALL adult
patients. The use of hematopoietic stem cell transplantation
(HSCT) is other option in these patients and non-myeloablative
conditioning is a friendly alternative to the conventional and more
toxic myeloablative radio-chemtotherapy scheme, but there is very
limited information using this kind of transplantation in ALL. We
prospectively evaluated the therapeutic value of non-myeloablative
conditioning HSCT in 43 high risk ALL patients in second or
subsequent remission. Patients and methods. Forty three ALL
high-risk patients were prospectively allografted, using HLA-iden-
tical siblings as donors. Patients received oral busulphan 4 mg /
Kg/2 days, i.v. cyclophosphamide 350 mg /m2/3 days and i.v.
ﬂudarabine 30 mg /m2/3 days; oral cyclosporin A 4 mg / Kg was
started on day - 1 and i.v. methotrexate 5 mg / m2 was delivered on
days  1,  3,  5 and  11. Median age of the patients was 19
years; there were 19 females. Patients received a median of 5.0 
106/ Kg CD34 cells. Results: Median time to achieve above 0.5 
109/L granulocytes was 14 days, whereas median time to achieve
above 20  109/L platelets was 15 days. Thirteen patients (30%)
are alive 491 days (median) after the HSCT. The 861-day proba-
bility of survival is 22%, whereas median survival is 200 days. Ten
patients (23%) developed acute graft versus-host disease (GVHD),
and 8 patients (18.6%) developed chronic GVHD. Twenty eight
(65%) patients showed relapse, in 9 cases despite the GVHD.
Thirty patients died between day 47 and 1050 after the HSCT,
most of them (70%) of an ALL relapse. The 100-day mortality was
25.5 %. Conclusion: Relapse remains the ﬁrst cause of death in
high-risk ALL patients. Non-myeloablative HCST seems to have
limited therapeutic effect in ALL patients with advanced disease.
New ideas and emerging strategies should be employed in order to
improve the outcome of these patients, like enhancement of graft-
versus leukemia effects and the use HSCT in ﬁrst complete remis-
sion.
241
NEUROLOGICAL COMPLICATIONS IN THE RECIPIENTS OF ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANT
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Gupta, V.1 1Blood and Marrow Transplant Program, Princess Margaret
Hospital, Toronto, ON, Canada; 2Department of Radiology, University
Health Network, Toronto; 3Department of Biostatistics, Princess Mar-
garet Hospital, Toronto.
The prevalence of neurological complications in allogeneic he-
matopoietic cell transplant (AlloHCT) recipients, the mechanisms
of its development, and its impact on outcome are not well deﬁned.
We reviewed the medical records of 302 consecutive patients, who
underwent AlloHCT for hematologic diseases at Princess Marga-
ret Hospital between January 2002 and November 2005. Patient,
disease and transplant related factors were systematically analyzed.
Stem cells were obtained via peripheral blood (n213) and bone
marrow (n89) from HLA-matched siblings/other family
(n224), HLA-matched unrelated donors (n52) and HLA-mis-
matched donors (n26). Median age of the recipients was 45 years
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